Growth Hormone Peptide GHRP-2 Suppresses Inflammation in Human Ovarian Cells Through Multiple Pathways | Research

The takeaway

GHRP-2 blocked inflammation in human ovarian cells by shutting down COX-2 and IL-8 production and accelerating their protein breakdown, revealing an unexpected anti-inflammatory role for ghrelin-type peptides.

Dual mechanism
GHRP-2 both blocked inflammatory protein production and accelerated breakdown of existing inflammatory proteins in ovarian cells

What the researchers found

GHRP-2 (a synthetic ghrelin analog) suppressed inflammation in human ovarian granulosa cells through multiple mechanisms. It reduced the expression and secretion of two key inflammatory mediators — COX-2 and IL-8 — by blocking the p38, JNK, and NF-κB signaling pathways that drive their production.

Beyond blocking production, GHRP-2 also accelerated the breakdown of already-existing COX-2 and IL-8 proteins by activating both proteasomal and lysosomal degradation pathways. The anti-inflammatory effect depended on two phosphatases (MKP-1 and PP2A), suggesting GHRP-2 works by activating the cell's own inflammation-shutoff switches.

Why it matters

GHRP-2 is primarily known as a growth hormone-releasing peptide, but this study reveals a completely separate function: powerful anti-inflammatory activity in reproductive cells. COX-2 and IL-8 drive inflammation during ovulation and in conditions like endometriosis and ovarian hyperstimulation syndrome. The finding that a ghrelin-receptor peptide can suppress ovarian inflammation through multiple mechanisms suggests growth hormone secretagogues may have therapeutic applications far beyond growth hormone release.

The numbers in context

COX-2 and IL-8 protein and mRNA reduced · PGE2 and IL-8 secretion reduced · p38 and JNK phosphorylation inhibited · NF-κB nuclear translocation blocked · AP-1 reporter activation reduced · MKP-1 and PP2A involvement confirmed

How the study worked

In vitro study using human ovarian granulosa KGN cells. Inflammation was induced with a protein kinase C activator (PDD). GHRP-2 was applied to assess anti-inflammatory effects. Researchers measured protein expression, mRNA levels, promoter activity, protein secretion, signaling pathway activation (Western blot, reporter assays), protein degradation pathways, and the role of specific phosphatases using inhibitors.

Who was studied

Human ovarian granulosa KGN cell line (in vitro)

What this study cannot tell us

Single cell line (KGN) — results may not apply to primary granulosa cells or the complex ovarian environment in vivo. Chemically induced inflammation (PDD) may not fully reflect physiological inflammatory processes during ovulation. No animal or human data. The dose of GHRP-2 used may not correspond to pharmacologically achievable concentrations in the ovary.

How to read the evidence

Preliminary evidence from a single in vitro study. The mechanistic depth is impressive — the study maps multiple signaling pathways comprehensively — but all findings are from one cell line with no in vivo validation. The clinical relevance of these concentrations in the human ovary is unknown.

When this study was published

Published in 2016. The anti-inflammatory properties of ghrelin-type peptides have continued to be explored since then, but this specific ovarian application remains at the basic research stage with no clinical follow-up.

The bigger picture

Growth hormone secretagogues like GHRP-2 and GHRP-6 are widely used in the peptide community primarily for growth hormone release. This study adds to growing evidence that these peptides have significant anti-inflammatory properties independent of GH release. The ovarian context is particularly relevant because inflammation plays a central role in ovulation, polycystic ovary syndrome, endometriosis, and IVF-related ovarian hyperstimulation. Understanding these non-GH effects could expand the therapeutic applications of ghrelin-receptor peptides.

Questions still open

Could GHRP-2's anti-inflammatory effect in ovarian cells translate to treatments for endometriosis or ovarian hyperstimulation syndrome?
Do other growth hormone secretagogues (GHRP-6, ipamorelin, MK-677) share this anti-inflammatory activity in reproductive tissues?
At what doses does GHRP-2 achieve anti-inflammatory effects in vivo, and does this overlap with growth hormone-stimulating doses?

Common questions

Isn't GHRP-2 used for growth hormone? Why is it anti-inflammatory?

GHRP-2 activates the ghrelin receptor, which is best known for stimulating growth hormone release. But this receptor is found in many tissues beyond the pituitary gland, including ovarian cells. This study shows that ghrelin receptor activation in ovarian cells triggers anti-inflammatory pathways — a completely separate function from growth hormone release. Many peptides have multiple roles depending on which tissue they act in.

Could this help with conditions like endometriosis or IVF complications?

Potentially, in the long term. Endometriosis and ovarian hyperstimulation syndrome both involve excessive inflammation in reproductive tissues. If GHRP-2's anti-inflammatory effects work in vivo (in a living body, not just in a lab dish), it could offer a new approach to managing these conditions. However, animal studies and then human clinical trials would be needed before any clinical use.

Read the original research

Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells.

International journal of molecular sciences, 17(8)

View on PubMed ↗Publisher’s paper ↗

Citation

Chao, Yi-Ning; Sun, David; Peng, Yen-Chun; Wu, Yuh-Lin. (2016). Growth Hormone Releasing Peptide-2 Attenuation of Protein Kinase C-Induced Inflammation in Human Ovarian Granulosa Cells.. International journal of molecular sciences, 17(8). https://doi.org/10.3390/ijms17081359